HomeNationCOVID-19 vaccine: Bharat Biotech to conduct Phase-3 trials on 26,000 volunteers in...

COVID-19 vaccine: Bharat Biotech to conduct Phase-3 trials on 26,000 volunteers in 25 centres

@the_news_21

Bharat Biotech, which is into developing Covaxin, a vaccine candidate for COVID-19, on Friday said it has successfully completed interim analysis of Phase I and II trials and is initiating Phase-III trials in 26,000 participants.

“After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India,” the vaccine maker said in a communication.

Covaxin is being developed byBharatBiotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

The city-based vaccine maker had on October 2 sought the Drug Controller General of India (DCGI)’s permission to conduct Phase 3 randomised double-blind placebo-controlled multi centre trial of its COVID-19 vaccine, sources said.

In July, the DCGI had given permission to Bharat Biotech to conduct Phase 1 and 2 clinical trials of its COVID-19 vaccine.

Subscribe to TheNews21

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

Stay Ahead with Independent Journalism

Investigations, political analysis and major national and global stories delivered directly to your inbox.

42 COMMENTS

  1. Upon the millions friendly strapping on fanduel casino Texas – the #1 tangible pelf casino app in America.
    Respite c start your $1000 OPERATE IT AGAIN gratuity and modify every spin, hand and rolling into official cash rewards.
    Irresponsibly payouts, huge jackpots, and habitual activity – download FanDuel Casino in these times and start playing like a pro today!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img

@the_news_21

Bharat Biotech, which is into developing Covaxin, a vaccine candidate for COVID-19, on Friday said it has successfully completed interim analysis of Phase I and II trials and is initiating Phase-III trials in 26,000 participants.

“After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India,” the vaccine maker said in a communication.

Covaxin is being developed byBharatBiotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

The city-based vaccine maker had on October 2 sought the Drug Controller General of India (DCGI)’s permission to conduct Phase 3 randomised double-blind placebo-controlled multi centre trial of its COVID-19 vaccine, sources said.

In July, the DCGI had given permission to Bharat Biotech to conduct Phase 1 and 2 clinical trials of its COVID-19 vaccine.

Html code here! Replace this with any non empty text and that's it.

42 COMMENTS

  1. Upon the millions friendly strapping on fanduel casino Texas – the #1 tangible pelf casino app in America.
    Respite c start your $1000 OPERATE IT AGAIN gratuity and modify every spin, hand and rolling into official cash rewards.
    Irresponsibly payouts, huge jackpots, and habitual activity – download FanDuel Casino in these times and start playing like a pro today!

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img